Astellas to Acquire Ocata Therapeutics - New Step Forward in Ophthalmology with Cell Therapy Approach Tokyo and Massachusetts, November 10, 2015 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, “Ocata”), a biotechnology company focused on the research and development of new therapies in the field of regenerative medicine, primarily cell therapy addressing unmet medical needs in ophthalmology patients, announced today that they have entered into a definitive agreement. Under the agre関連タグ:
日付 | 始値 | 高値 | 安値 | 終値 | 出来高 |
---|---|---|---|---|---|
2015-11-20 | 1720 | 1744 | 1718 | 1740 | 7192400 |
2015-11-19 | 1760 | 1765 | 1730 | 1734 | 9589300 |
2015-11-18 | 1730 | 1753 | 1725 | 1732 | 8682800 |
2015-11-17 | 1752 | 1754 | 1721 | 1726 | 10090900 |
2015-11-16 | 1730 | 1748 | 1708 | 1737 | 6267900 |
2015-11-13 | 1762 | 1762 | 1735 | 1753 | 7800800 |
2015-11-12 | 1764 | 1793 | 1745 | 1770 | 7977700 |
2015-11-11 | 1784 | 1784 | 1731 | 1764 | 9881100 |
2015-11-10 | 1773 | 1801 | 1770 | 1801 | 8662200 |
2015-11-09 | 1776 | 1804 | 1772 | 1802 | 8390200 |
2015-11-06 | 1768 | 1789 | 1762 | 1786 | 4487800 |
2015-11-05 | 1765 | 1784 | 1761 | 1768 | 7400400 |
2015-11-04 | 1740 | 1782 | 1740 | 1751 | 9608200 |
2015-11-02 | 1748 | 1759 | 1708 | 1718 | 7785500 |